AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18564391 — intervention group
Group type: COMPARATOR
Intervention: Leukoreduced autologous whole blood
Number of subjects: 1089
Study 16321914 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic access
Number of subjects: 304
Study 16321914 — intervention group
Group type: COMPARATOR
Intervention: Human access
Number of subjects: 304
Study 16321914 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans‐Atlantic robotic access
Number of subjects: 304
Study 16321914 — intervention group
Group type: EXPERIMENTAL
Intervention: Local robotic access
Number of subjects: 304
Study 12094254 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF and VEGFR-2 expression in AML patients
Number of subjects: 32
Study 12094254 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF expression in AML patients with high microvessel density
Number of subjects: 32
Study 12094254 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFR-2 expression in AML patients with high microvessel density
Number of subjects: 32
Study 12094254 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of VEGF with bone marrow microvessel density
Number of subjects: 32
Study 12094254 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of VEGFR-2 with bone marrow microvessel density
Number of subjects: 32
Study 12094254 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFR-2 staining levels post-complete remission
Number of subjects: 32
Study 10605904 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy in obese patients (Group I)
Number of subjects: 145
Study 10605904 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy in nonobese patients (Group II)
Number of subjects: 145
Study 8542325 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (0.05 mg, 0.5 mg or 5 mg)
Number of subjects: 6
Study 8542325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1954418 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 1 diet with individual intervention
Number of subjects: 16
Study 1954418 — intervention group
Group type: EXPERIMENTAL
Intervention: Population education
Number of subjects: 16
Study 1954418 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined population and individual dietary advice
Number of subjects: 16
Study 1954418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diets more rigorous than step 2 diet
Number of subjects: 16
Study 7070696 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (270 mg/die per os)
Number of subjects: 20
Study 7070696 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (270 mg/die per os)
Number of subjects: 20
Study 31451207 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (200 μg-6 μg Turbuhaler, one inhalation as needed)
Number of subjects: 885
Study 31451207 — intervention group
Group type: COMPARATOR
Intervention: Maintenance budesonide (200 μg Turbuhaler, one inhalation twice daily) plus terbutaline (250 μg Turbuhaler, two inhalations as needed)
Number of subjects: 885
Study 31451207 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol
Number of subjects: 885
Study 28114551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering off asthma medications over 4 study visits
Number of subjects: 701
Study 28114551 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 12 months
Number of subjects: 701
Study 28114551 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial diagnostic workup for asthma in the community
Number of subjects: 701
Study 26460886 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose edoxaban (HDE, 60 mg/30 mg)
Number of subjects: 21105
Study 26460886 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose edoxaban (LDE, 30 mg/15 mg)
Number of subjects: 21105
Study 26460886 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 21105
Study 25632577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion of Neixiyan (EX-HE4) and Waixiyan (ST 35) for 30 min, once daily for 14 days, followed by moxibustion of Yaoyangguan (GV 3) and Mingmen (GV 4) once daily for next 7 days.
Number of subjects: 59
Study 25632577 — intervention group
Group type: COMPARATOR
Intervention: Mild moxibustion of Neixiyan (EX-HE4) and Waixiyan (ST 35) for 30 min, once daily for 14 days (control group).
Number of subjects: 59
Study 23072406 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D visualization
Number of subjects: 33
Study 23072406 — intervention group
Group type: COMPARATOR
Intervention: 2D visualization
Number of subjects: 33
Study 19546252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) 0.75 to 1.3 g as a 2‐hour infusion
Number of subjects: 2
Study 19546252 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg intravenous
Number of subjects: 2
Study 17069812 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery occlusion and subsequent minilaparotomy and myomectomy (group I)
Number of subjects: 82
Study 17069812 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy alone (group II)
Number of subjects: 82
Study 16796640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine gel 4%
Number of subjects: 3
Study 16796640 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 3
Study 14682411 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) levels in exhaled breath condensate of COPD patients
Number of subjects: 28
Study 14682411 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) levels in exhaled breath condensate of healthy non-smokers
Number of subjects: 28
Study 10829583 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 96
Study 10829583 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 96
Study 10829583 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandins (Iloprost and Alprostadil)
Number of subjects: 96
Study 8800399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 28
Study 8800399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8800399 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive living arrangements after hospital discharge
Number of subjects: 28
Study 8800399 — intervention group
Group type: COMPARATOR
Intervention: Community discharge
Number of subjects: 28
Study 8800399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependence
Number of subjects: 28
Study 1622739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasplenic arterial infusion of interleukin-2 (IS-IL-2)
Number of subjects: 18
Study 6370634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 26
Study 6370634 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 26
Study 30805949 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282 1 mg
Number of subjects: 43
Study 30805949 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282 3 mg
Number of subjects: 43
Study 30962251 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with low non-immune-mediated HR (n=61)
Number of subjects: 137
Study 30962251 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with intermediate non-immune-mediated HR (n=52)
Number of subjects: 137
Study 30962251 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with high non-immune-mediated HR (n=24)
Number of subjects: 137
Study 30962251 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with low immune-mediated HR
Number of subjects: 137
Study 30962251 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with intermediate immune-mediated HR
Number of subjects: 137
Study 30962251 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with high immune-mediated HR
Number of subjects: 137
Study 28528859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine A (CyA) at 3 mg/kg divided twice daily for 3 months
Number of subjects: 26
Study 25768026 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive periventricular device occlusion (MIPDO)
Number of subjects: 538
Study 25768026 — intervention group
Group type: COMPARATOR
Intervention: Right subaxillary incision surgical repair (RSISR)
Number of subjects: 538
Study 25768026 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of MIPDO and RSISR
Number of subjects: 538
Study 23458037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2%) and tramadol (2 mg/kg) combination
Number of subjects: 34
Study 23458037 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (2%) alone
Number of subjects: 34
Study 21078131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressing
Number of subjects: 281
Study 21078131 — intervention group
Group type: COMPARATOR
Intervention: Cadexomer iodine dressing
Number of subjects: 281
Study 18424221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic treatment in patients with PD
Number of subjects: 37
Study 18424221 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 37
Study 18424221 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-naïve patients with PD
Number of subjects: 37
Study 18424221 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (predictable task)
Number of subjects: 37
Study 18424221 — intervention group
Group type: COMPARATOR
Intervention: Controls (post-training test)
Number of subjects: 37
Study 18424221 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (post-training test)
Number of subjects: 37
Study 16900801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 80
Study 16900801 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 80
Study 15297088 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN)
Number of subjects: 52
Study 15297088 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral nutrition (EN)
Number of subjects: 52
Study 11345755 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide and oxygen
Number of subjects: 60
Study 11345755 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 60
Study 9218740 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 347
Study 9218740 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 347
Study 7678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid diet
Number of subjects: 56
Study 7678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid diet
Number of subjects: 56
Study 7678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed children
Number of subjects: 56
Study 7678713 — intervention group
Group type: COMPARATOR
Intervention: Non-breast-fed children
Number of subjects: 56
Study 7678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary viscosity (with or without added amylase)
Number of subjects: 56
Study 3329532 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg terbutaline by metered dose inhaler (MDI)
Number of subjects: 9
Study 3329532 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline subcutaneously (SC)
Number of subjects: 9
Study 3329532 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo SC plus 2 mg terbutaline by MDI
Number of subjects: 9
Study 3329532 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg terbutaline SC plus placebo by MDI
Number of subjects: 9
Study 3329532 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 9
Study 31779791 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder monitoring
Number of subjects: 590
Study 27997482 — intervention group
Group type: EXPERIMENTAL
Intervention: NIATx intervention
Number of subjects: 16
Study 27997482 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping On
Number of subjects: 16
Study 27997482 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSMP
Number of subjects: 16
Study 27997482 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 16
Study 26138284 — intervention group
Group type: EXPERIMENTAL
Intervention: Program group (educational program)
Number of subjects: 215
Study 26138284 — intervention group
Group type: EXPERIMENTAL
Intervention: Text group (textbook reading)
Number of subjects: 215
Study 26138284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 215
Study 22782463 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus cisplatin (XP)
Number of subjects: 144
Study 21265818 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 90
Study 21265818 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study 21265818 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium in patients with baseline Warters scale >3
Number of subjects: 90
Study 18948612 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 IU)
Number of subjects: 24
Study 18948612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16861415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (5 mg)
Number of subjects: 12
Study 16861415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (5 mg)
Number of subjects: 12
Study 16861415 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (5 mg)
Number of subjects: 12
Study 12959636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 16
Study 12959636 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 80 mg/day
Number of subjects: 16
Study 14676756 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 grams of pheneticillin administered orally one hour before surgery
Number of subjects: 20
Study 14676756 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally one hour before surgery
Number of subjects: 20
Study 10967612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy breakfast (2920 kJ / 700 kcal)
Number of subjects: 10
Study 10967612 — intervention group
Group type: COMPARATOR
Intervention: Low-energy breakfast (418 kJ / 100 kcal)
Number of subjects: 10
Study 8864962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 8
Study 8864962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol ester margarine (3 g/day)
Number of subjects: 8
Study 8864962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pravastatin and sitostanol ester margarine
Number of subjects: 8
Study 8864962 — intervention group
Group type: COMPARATOR
Intervention: Control margarine (24 g daily)
Number of subjects: 8
Study 1992960 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise test at entry
Number of subjects: 3617
Study 1992960 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visit with newly positive test result
Number of subjects: 3617
Study 1992960 — intervention group
Group type: EXPERIMENTAL
Intervention: Any positive test result during the study (mean number of tests per subject, 6.2)
Number of subjects: 3617
Study 6084139 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (average daily dosage 16 to 31 mg)
Number of subjects: 147
Study 6084139 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ, average daily dosage 50 to 75 mg)
Number of subjects: 147
Study 31256096 — intervention group
Group type: COMPARATOR
Intervention: Standard Dix-Hallpike test
Number of subjects: 0
Study 31256096 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Dix-Hallpike test with a pillow under shoulders
Number of subjects: 0
Study 31256096 — intervention group
Group type: COMPARATOR
Intervention: Both tests (Standard and Modified)
Number of subjects: 0
Study 30001202 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant low-level laser therapy
Number of subjects: 40
Study 30001202 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (topical medication and compressive therapy)
Number of subjects: 40
Study 27300579 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily = 100 mg/d)
Number of subjects: 24
Study 27300579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg once daily for diet, 50 mg twice daily for metformin = 100 mg/d)
Number of subjects: 24
Study 27300579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 24
Study 25013000 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Number of subjects: 172
Study 25013000 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 172
Study 22672148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led education and monitoring programme (n = 23)
Number of subjects: 46
Study 22672148 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 46
Study 20608254 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18073360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 106
Study 18073360 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 106
Study 16138073 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicar (100 mg/kg over 15 minutes, maintenance 10 mg/kg per hour until wound closure)
Number of subjects: 28
Study 16138073 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 16138073 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicar (in postoperative suction drainage)
Number of subjects: 28
Study 16138073 — intervention group
Group type: COMPARATOR
Intervention: Control (in postoperative suction drainage)
Number of subjects: 28
Study 16138073 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicar (in same-day anterior and posterior spinal surgery)
Number of subjects: 28
Study 16138073 — intervention group
Group type: COMPARATOR
Intervention: Control (no Amicar)
Number of subjects: 28
Study 12103285 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted colectomy (LAC)
Number of subjects: 219
Study 12103285 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 219
Study 10463091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-hour workshop on breast cyst aspiration (BCA)
Number of subjects: 69
Study 10463091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 69
Study 7540965 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 18000
Study 7540965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one matching tablet per day)
Number of subjects: 18000
Study 1975851 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide pressurised aerosol 400 micrograms twice daily
Number of subjects: 77
Study 1975851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 762813 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine (0.125 to 0.250 mg) plus Hydroflumethiazide (50 or 100 mg)
Number of subjects: 59
Study 762813 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (500 to 2,000 mg) plus Hydroflumethiazide (50 or 100 mg)
Number of subjects: 59
Study 762813 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 to 320 mg) plus Hydroflumethiazide (50 or 100 mg)
Number of subjects: 59
Study 29796932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytate wholegrain bread (200 g/day)
Number of subjects: 102
Study 29796932 — intervention group
Group type: COMPARATOR
Intervention: High-phytate wholegrain bread (200 g/day)
Number of subjects: 102
Study 27464609 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion lymphadenectomy (CLND)
Number of subjects: 2172
Study 27464609 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 2172
Study 26745689 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol brief intervention
Number of subjects: 660
Study 26745689 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 660
Study 23986780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 18
Study 23986780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi plus antihypertensive drugs
Number of subjects: 18
Study 23986780 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 18
Study 23986780 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs
Number of subjects: 18
Study 21845243 — intervention group
Group type: EXPERIMENTAL
Intervention: MCBS with recombinant human platelet‐derived growth factor BB [rhPDGF‐BB; 0.3 mg/mL]
Number of subjects: 16
Study 21845243 — intervention group
Group type: EXPERIMENTAL
Intervention: MCBS with enamel matrix derivative [EMD]
Number of subjects: 16
Study 21845243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EMD with bone ceramic
Number of subjects: 16
Study 21845243 — intervention group
Group type: COMPARATOR
Intervention: Mineral collagen bone substitute [MCBS] scaffold alone
Number of subjects: 16
Study 18663294 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE Protocol P1 (L(1) = 60, L(2) = 50 dB SPL)
Number of subjects: 1550
Study 18663294 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE Protocol P2 (L(1) = 65, L(2) = 55 dB SPL)
Number of subjects: 1550
Study 18663294 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE Protocol P3 (L(1) = 75, L(2) = 65 dB SPL)
Number of subjects: 1550
Study 18663294 — intervention group
Group type: COMPARATOR
Intervention: Standard TEOAE test
Number of subjects: 1550
Study 16581481 — intervention group
Group type: COMPARATOR
Intervention: Doppler tissue imaging (DTI)
Number of subjects: 131
Study 14681716 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperosmolality induced by fluid restriction and intravenous infusion of hypertonic NaCl (2‐5%, wt/vol) during 17 h
Number of subjects: 10
Study 14681716 — intervention group
Group type: EXPERIMENTAL
Intervention: hypo‐osmolality produced by intravenous administration of desmopressin, liberal water drinking and infusion of hypotonic saline (0.4%)
Number of subjects: 10